510(k) Report

FDA applicant

Caredx, Inc.

Brisbane, CA1 decision2023–20230 recalls

FDA records 1 decision for Caredx, Inc. (Brisbane, CA) in 2023: 1 510(k) clearance. All are in product code OJQ (Cardiac Allograft Gene Expression Profiling…). Its devices cite 1 predicate, 0 of them its own earlier devices. No recall is linked to its devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, cardiovascular panel, where it files most

How often FDA has decided Caredx, Inc.’s devices, and how often a recall has named them.

FDA decisions per year

1in 2023

2023: 1
2023high 1 (2023) · low 0 (2024)2026

2026 so far, outlined.

Recalls per year

No recall linked to its devices since 2023.

FIG. 1 — Caredx, Inc. by year, 2023–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Caredx, Inc.’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Which product codes does it file in?

  • OJQCardiac Allograft Gene Expression Profiling Test System1decision

Whose devices does it build on?

Its devices cite 1 predicate; 0 are its own earlier devices. The firms it cites most:

What has FDA decided for it lately?

  • K221640AlloMap Heart Molecular Expression TestingCaredx, Inc. · 2023

The one decision as Caredx, Inc. →